Drawing from years of experience in pediatric medicine, Andrew Mulberg, Senior Director of Clinical Research & Development, Johnson and Johnson, LLC felt there was an unmet need for a textbook devoted to an understanding of the issues surrounding development of pharmaceutical-based therapies in pediatric drug development. As an outgrowth of this passion for pediatric medicine, he set out to complete the first comprehensive book detailing the concepts and applications of pediatric drug development.
Today, the product of his work and his passion has yielded his second publication, entitled, Pediatric Drug Development: Concepts and Applications published by Wiley Blackwell. Created in collaboration with Steve A. Silber, Vice President of Established Products at J&JPRD and John van den Anker, Professor of Pediatric Clinical Pharmacology, Children's National Medical Center, Washington, DC and many of his J&JPRD/academic/ government colleagues, Pediatric Drug Development: Concepts and Applications was designed as both a reference and a textbook.
The publication explores the scientific differences between the pediatric and the adult subject in the development of medicines, while taking into account the ethics and medical needs of pediatric patients. In addition, the book examines the overarching business case for the proper development of drugs for children, as well as the technical feasibility studies and processes that are necessary for a successful program. The book aims to provide the information necessary to ensure better and safer drugs for pediatric patients.
For more information on Pediatric Drug Development: Concepts and Applications, please click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.